請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28971
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 孔繁璐(Fan-Lu Kung) | |
dc.contributor.author | Fan-Lun Liu | en |
dc.contributor.author | 劉凡綸 | zh_TW |
dc.date.accessioned | 2021-06-13T00:32:32Z | - |
dc.date.available | 2009-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-26 | |
dc.identifier.citation | 1. Beach, T.G., Kuo, Y.M., Spiegel, K., Emmerling, M.R., Sue, L.I., Kokjohn, K. & Roher, A.E. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. Journal of neuropathology and experimental neurology 59, 308-313 (2000).
2. Braak, H. & Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiology of aging 16, 271-278; discussion 278-284 (1995). 3. Braak, H. & Braak, E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiology of aging 18, S85-88 (1997). 4. Nagy, Z., Hindley, N.J., Braak, H., Braak, E., Yilmazer-Hanke, D.M., Schultz, C., Barnetson, L., King, E.M., Jobst, K.A. & Smith, A.D. The progression of Alzheimer's disease from limbic regions to the neocortex: clinical, radiological and pathological relationships. Dementia and geriatric cognitive disorders 10, 115-120 (1999). 5. Williamson, J. & LaRusse, S. Genetics and genetic counseling: recommendations for Alzheimer's disease, frontotemporal dementia, and Creutzfeldt-Jakob disease. Current neurology and neuroscience reports 4, 351-357 (2004). 6. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L. & Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America 82, 4245-4249 (1985). 7. Russo, C., Salis, S., Dolcini, V., Venezia, V., Song, X.H., Teller, J.K. & Schettini, G. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. Neurobiology of disease 8, 173-180 (2001). 8. Chang, K.A. & Suh, Y.H. Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. Journal of pharmacological sciences 97, 461-471 (2005). 9. Walker, L.C., Ibegbu, C.C., Todd, C.W., Robinson, H.L., Jucker, M., LeVine, H., 3rd & Gandy, S. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochemical pharmacology 69, 1001-1008 (2005). 10. Kosik, K.S. Tau protein and neurodegeneration. Molecular neurobiology 4, 171-179 (1990). 11. Storey, E. & Cappai, R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathology and applied neurobiology 25, 81-97 (1999). 12. Golde, T.E., Eckman, C.B. & Younkin, S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochimica et biophysica acta 1502, 172-187 (2000). 13. Glenner, G.G. & Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and biophysical research communications 120, 885-890 (1984). 14. Yoshikai, S., Sasaki, H., Doh-ura, K., Furuya, H. & Sakaki, Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 87, 257-263 (1990). 15. Lamb, B.T., Sisodia, S.S., Lawler, A.M., Slunt, H.H., Kitt, C.A., Kearns, W.G., Pearson, P.L., Price, D.L. & Gearhart, J.D. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nature genetics 5, 22-30 (1993). 16. Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S. & Ito, H. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature 331, 530-532 (1988). 17. Koo, E.H., Sisodia, S.S., Archer, D.R., Martin, L.J., Weidemann, A., Beyreuther, K., Fischer, P., Masters, C.L. & Price, D.L. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proceedings of the National Academy of Sciences of the United States of America 87, 1561-1565 (1990). 18. Selkoe, D.J. Normal and abnormal biology of the beta-amyloid precursor protein. Annual review of neuroscience 17, 489-517 (1994). 19. Moya, K.L., Confaloni, A.M. & Allinquant, B. In vivo neuronal synthesis and axonal transport of Kunitz protease inhibitor (KPI)-containing forms of the amyloid precursor protein. Journal of neurochemistry 63, 1971-1974 (1994). 20. Vetrivel, K.S. & Thinakaran, G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66, S69-73 (2006). 21. Kim, S.H. & Suh, Y.H. Neurotoxicity of a carboxyl-terminal fragment of the Alzheimer's amyloid precursor protein. Journal of neurochemistry 67, 1172-1182 (1996). 22. Venezia, V., Russo, C., Repetto, E., Nizzari, M., Violani, E., Carlo, P., Marchetti, B. & Schettini, G. Apoptotic cell death and amyloid precursor protein signaling in neuroblastoma SH-SY5Y cells. Annals of the New York Academy of Sciences 1030, 339-347 (2004). 23. Lu, D.C., Rabizadeh, S., Chandra, S., Shayya, R.F., Ellerby, L.M., Ye, X., Salvesen, G.S., Koo, E.H. & Bredesen, D.E. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nature medicine 6, 397-404 (2000). 24. Tanzi, R.E., Kovacs, D.M., Kim, T.W., Moir, R.D., Guenette, S.Y. & Wasco, W. The gene defects responsible for familial Alzheimer's disease. Neurobiology of disease 3, 159-168 (1996). 25. Tanahashi, H. & Tabira, T. Genome structure and chromosomal mapping of the gene for Fe65L2 interacting with Alzheimer's beta-amyloid precursor protein. Biochemical and biophysical research communications 258, 385-389 (1999). 26. Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St George-Hyslop, P. & Checler, F. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 26, 6377-6385 (2006). 27. Ozaki, T., Li, Y., Kikuchi, H., Tomita, T., Iwatsubo, T. & Nakagawara, A. The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis. Biochemical and biophysical research communications 351, 57-63 (2006). 28. Esposito, L., Gan, L., Yu, G.Q., Essrich, C. & Mucke, L. Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. J Neurochem 91, 1260-1274 (2004). 29. Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C. & Fahrenholz, F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proceedings of the National Academy of Sciences of the United States of America 96, 3922-3927 (1999). 30. Marcinkiewicz, M. & Seidah, N.G. Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. Journal of neurochemistry 75, 2133-2143 (2000). 31. Sagane, K., Hayakawa, K., Kai, J., Hirohashi, T., Takahashi, E., Miyamoto, N., Ino, M., Oki, T., Yamazaki, K. & Nagasu, T. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC neuroscience 6, 33 (2005). 32. White, J.M. ADAMs: modulators of cell-cell and cell-matrix interactions. Current opinion in cell biology 15, 598-606 (2003). 33. Vassar, R. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J Mol Neurosci 17, 157-170 (2001). 34. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins, F., Treanor, J., Rogers, G. & Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (New York, N.Y 286, 735-741 (1999). 35. Sinha, S., Anderson, J.P., Barbour, R., Basi, G.S., Caccavello, R., Davis, D., Doan, M., Dovey, H.F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S.M., Wang, S., Walker, D., Zhao, J., McConlogue, L. & John, V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-540 (1999). 36. Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J.C., Yan, Q., Richards, W.G., Citron, M. & Vassar, R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature neuroscience 4, 231-232 (2001). 37. Westmeyer, G.G., Willem, M., Lichtenthaler, S.F., Lurman, G., Multhaup, G., Assfalg-Machleidt, I., Reiss, K., Saftig, P. & Haass, C. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. The Journal of biological chemistry 279, 53205-53212 (2004). 38. Harada, H., Tamaoka, A., Ishii, K., Shoji, S., Kametaka, S., Kametani, F., Saito, Y. & Murayama, S. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neuroscience research 54, 24-29 (2006). 39. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L. & Wong, P.C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nature neuroscience 4, 233-234 (2001). 40. Bodendorf, U., Danner, S., Fischer, F., Stefani, M., Sturchler-Pierrat, C., Wiederhold, K.H., Staufenbiel, M. & Paganetti, P. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. Journal of neurochemistry 80, 799-806 (2002). 41. Levitan, D. & Greenwald, I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377, 351-354 (1995). 42. De Strooper, B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38, 9-12 (2003). 43. Vetrivel, K.S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P.C., Xu, H. & Thinakaran, G. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. The Journal of biological chemistry 279, 44945-44954 (2004). 44. Chen, F., Hasegawa, H., Schmitt-Ulms, G., Kawarai, T., Bohm, C., Katayama, T., Gu, Y., Sanjo, N., Glista, M., Rogaeva, E., Wakutani, Y., Pardossi-Piquard, R., Ruan, X., Tandon, A., Checler, F., Marambaud, P., Hansen, K., Westaway, D., St George-Hyslop, P. & Fraser, P. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440, 1208-1212 (2006). 45. Lee, S.F., Shah, S., Yu, C., Wigley, W.C., Li, H., Lim, M., Pedersen, K., Han, W., Thomas, P., Lundkvist, J., Hao, Y.H. & Yu, G. A conserved GXXXG motif in APH-1 is critical for assembly and activity of the gamma-secretase complex. The Journal of biological chemistry 279, 4144-4152 (2004). 46. Zhang, Y.W., Luo, W.J., Wang, H., Lin, P., Vetrivel, K.S., Liao, F., Li, F., Wong, P.C., Farquhar, M.G., Thinakaran, G. & Xu, H. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. The Journal of biological chemistry 280, 17020-17026 (2005). 47. Watanabe, N., Tomita, T., Sato, C., Kitamura, T., Morohashi, Y. & Iwatsubo, T. Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. The Journal of biological chemistry 280, 41967-41975 (2005). 48. Wolozin, B. A fluid connection: cholesterol and Abeta. Proceedings of the National Academy of Sciences of the United States of America 98, 5371-5373 (2001). 49. Simons, K. & Toomre, D. Lipid rafts and signal transduction. Nature reviews 1, 31-39 (2000). 50. Bickel, P.E., Scherer, P.E., Schnitzer, J.E., Oh, P., Lisanti, M.P. & Lodish, H.F. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. The Journal of biological chemistry 272, 13793-13802 (1997). 51. Ikezu, T., Trapp, B.D., Song, K.S., Schlegel, A., Lisanti, M.P. & Okamoto, T. Caveolae, plasma membrane microdomains for alpha-secretase-mediated processing of the amyloid precursor protein. The Journal of biological chemistry 273, 10485-10495 (1998). 52. Chen, T.Y., Liu, P.H., Ruan, C.T., Chiu, L. & Kung, F.L. The intracellular domain of amyloid precursor protein interacts with flotillin-1, a lipid raft protein. Biochemical and biophysical research communications 342, 266-272 (2006). 53. Nishiyama, K., Trapp, B.D., Ikezu, T., Ransohoff, R.M., Tomita, T., Iwatsubo, T., Kanazawa, I., Hsiao, K.K., Lisanti, M.P. & Okamoto, T. Caveolin-3 upregulation activates beta-secretase-mediated cleavage of the amyloid precursor protein in Alzheimer's disease. J Neurosci 19, 6538-6548 (1999). 54. Kokubo, H., Lemere, C.A. & Yamaguchi, H. Localization of flotillins in human brain and their accumulation with the progression of Alzheimer's disease pathology. Neuroscience letters 290, 93-96 (2000). 55. Hattori, C., Asai, M., Onishi, H., Sasagawa, N., Hashimoto, Y., Saido, T.C., Maruyama, K., Mizutani, S. & Ishiura, S. BACE1 interacts with lipid raft proteins. Journal of neuroscience research 84, 912-917 (2006). 56. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C.G. & Simons, K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America 95, 6460-6464 (1998). 57. Fassbender, K., Masters, C. & Beyreuther, K. Alzheimer's disease: molecular concepts and therapeutic targets. Die Naturwissenschaften 88, 261-267 (2001). 58. Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. The Journal of cell biology 160, 113-123 (2003). 59. Yazaki, M., Tagawa, K., Maruyama, K., Sorimachi, H., Tsuchiya, T., Ishiura, S. & Suzuki, K. Mutation of potential N-linked glycosylation sites in the Alzheimer's disease amyloid precursor protein (APP). Neuroscience letters 221, 57-60 (1996). 60. Tomita, S., Kirino, Y. & Suzuki, T. Cleavage of Alzheimer's amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. The Journal of biological chemistry 273, 6277-6284 (1998). 61. Ando, K., Iijima, K.I., Elliott, J.I., Kirino, Y. & Suzuki, T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. The Journal of biological chemistry 276, 40353-40361 (2001). 62. Vingtdeux, V., Hamdane, M., Gompel, M., Begard, S., Drobecq, H., Ghestem, A., Grosjean, M.E., Kostanjevecki, V., Grognet, P., Vanmechelen, E., Buee, L., Delacourte, A. & Sergeant, N. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiology of disease 20, 625-637 (2005). 63. Lai, A., Sisodia, S.S. & Trowbridge, I.S. Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. The Journal of biological chemistry 270, 3565-3573 (1995). 64. Zheng, P., Eastman, J., Vande Pol, S. & Pimplikar, S.W. PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 95, 14745-14750 (1998). 65. Koo, E.H., Squazzo, S.L., Selkoe, D.J. & Koo, C.H. Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. Journal of cell science 109 ( Pt 5), 991-998 (1996). 66. Kuentzel, S.L., Ali, S.M., Altman, R.A., Greenberg, B.D. & Raub, T.J. The Alzheimer beta-amyloid protein precursor/protease nexin-II is cleaved by secretase in a trans-Golgi secretory compartment in human neuroglioma cells. The Biochemical journal 295 ( Pt 2), 367-378 (1993). 67. Suzuki, T., Oishi, M., Marshak, D.R., Czernik, A.J., Nairn, A.C. & Greengard, P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. The EMBO journal 13, 1114-1122 (1994). 68. Oishi, M., Nairn, A.C., Czernik, A.J., Lim, G.S., Isohara, T., Gandy, S.E., Greengard, P. & Suzuki, T. The cytoplasmic domain of Alzheimer's amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Molecular medicine (Cambridge, Mass 3, 111-123 (1997). 69. Gandy, S., Czernik, A.J. & Greengard, P. Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Proceedings of the National Academy of Sciences of the United States of America 85, 6218-6221 (1988). 70. Fauser, S., Luberichs, J., Besch, D. & Leo-Kottler, B. Sequence analysis of the complete mitochondrial genome in patients with Leber's hereditary optic neuropathy lacking the three most common pathogenic DNA mutations. Biochemical and biophysical research communications 295, 342-347 (2002). 71. Zambrano, N., Bruni, P., Minopoli, G., Mosca, R., Molino, D., Russo, C., Schettini, G., Sudol, M. & Russo, T. The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene. The Journal of biological chemistry 276, 19787-19792 (2001). 72. Liu, F., Su, Y., Li, B., Zhou, Y., Ryder, J., Gonzalez-DeWhitt, P., May, P.C. & Ni, B. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS letters 547, 193-196 (2003). 73. Iijima, K., Ando, K., Takeda, S., Satoh, Y., Seki, T., Itohara, S., Greengard, P., Kirino, Y., Nairn, A.C. & Suzuki, T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. Journal of neurochemistry 75, 1085-1091 (2000). 74. Lee, M.S., Kao, S.C., Lemere, C.A., Xia, W., Tseng, H.C., Zhou, Y., Neve, R., Ahlijanian, M.K. & Tsai, L.H. APP processing is regulated by cytoplasmic phosphorylation. The Journal of cell biology 163, 83-95 (2003). 75. Lu, K.P., Hanes, S.D. & Hunter, T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380, 544-547 (1996). 76. Sudol, M. & Hunter, T. NeW wrinkles for an old domain. Cell 103, 1001-1004 (2000). 77. Pathan, N., Aime-Sempe, C., Kitada, S., Haldar, S. & Reed, J.C. Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia (New York, N.Y 3, 70-79 (2001). 78. Shen, M., Stukenberg, P.T., Kirschner, M.W. & Lu, K.P. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes & development 12, 706-720 (1998). 79. Winkler, K.E., Swenson, K.I., Kornbluth, S. & Means, A.R. Requirement of the prolyl isomerase Pin1 for the replication checkpoint. Science (New York, N.Y 287, 1644-1647 (2000). 80. Pastorino, L., Sun, A., Lu, P.J., Zhou, X.Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.H., Li, X., Xia, W., Nicholson, L.K. & Lu, K.P. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440, 528-534 (2006). 81. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. & Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (New York, N.Y 274, 99-102 (1996). 82. Sultana, R., Boyd-Kimball, D., Poon, H.F., Cai, J., Pierce, W.M., Klein, J.B., Markesbery, W.R., Zhou, X.Z., Lu, K.P. & Butterfield, D.A. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiology of aging 27, 918-925 (2006). 83. Roe, C.M., Behrens, M.I., Xiong, C., Miller, J.P. & Morris, J.C. Alzheimer disease and cancer. Neurology 64, 895-898 (2005). 84. LeBlanc, A.C., Koutroumanis, M. & Goodyer, C.G. Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures. J Neurosci 18, 2907-2913 (1998). 85. Jin, L.W., Ninomiya, H., Roch, J.M., Schubert, D., Masliah, E., Otero, D.A. & Saitoh, T. Peptides containing the RERMS sequence of amyloid beta/A4 protein precursor bind cell surface and promote neurite extension. J Neurosci 14, 5461-5470 (1994). 86. Cai, X.D., Golde, T.E. & Younkin, S.G. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science (New York, N.Y 259, 514-516 (1993). 87. Perez, R.G., Squazzo, S.L. & Koo, E.H. Enhanced release of amyloid beta-protein from codon 670/671 'Swedish' mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. The Journal of biological chemistry 271, 9100-9107 (1996). 88. Koo, E.H. & Squazzo, S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. The Journal of biological chemistry 269, 17386-17389 (1994). 89. Martin, B.L., Schrader-Fischer, G., Busciglio, J., Duke, M., Paganetti, P. & Yankner, B.A. Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. The Journal of biological chemistry 270, 26727-26730 (1995). 90. Stephens, D.J. & Austen, B.M. Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells. Journal of neuroscience research 46, 211-225 (1996). 91. Lazarov, V.K., Fraering, P.C., Ye, W., Wolfe, M.S., Selkoe, D.J. & Li, H. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proceedings of the National Academy of Sciences of the United States of America 103, 6889-6894 (2006). 92. Tolia, A., Chavez-Gutierrez, L. & De Strooper, B. Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex. The Journal of biological chemistry 281, 27633-27642 (2006). 93. Esler, W.P. & Wolfe, M.S. A portrait of Alzheimer secretases--new features and familiar faces. Science (New York, N.Y 293, 1449-1454 (2001). 94. Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (New York, N.Y 297, 353-356 (2002). 95. Mattson, M.P. Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (2004). 96. Okochi, M., Steiner, H., Fukumori, A., Tanii, H., Tomita, T., Tanaka, T., Iwatsubo, T., Kudo, T., Takeda, M. & Haass, C. Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. The EMBO journal 21, 5408-5416 (2002). 97. Lammich, S., Okochi, M., Takeda, M., Kaether, C., Capell, A., Zimmer, A.K., Edbauer, D., Walter, J., Steiner, H. & Haass, C. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. The Journal of biological chemistry 277, 44754-44759 (2002). 98. Markus, P.M., Cai, X., Ming, W., Demetris, A.J., Fung, J.J. & Starzl, T.E. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 52, 590-594 (1991). 99. Jayaraman, T., Brillantes, A.M., Timerman, A.P., Fleischer, S., Erdjument-Bromage, H., Tempst, P. & Marks, A.R. FK506 binding protein associated with the calcium release channel (ryanodine receptor). The Journal of biological chemistry 267, 9474-9477 (1992). 100. Cameron, A.M., Steiner, J.P., Sabatini, D.M., Kaplin, A.I., Walensky, L.D. & Snyder, S.H. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proceedings of the National Academy of Sciences of the United States of America 92, 1784-1788 (1995). 101. Ahern, G.P., Junankar, P.R. & Dulhunty, A.F. Subconductance states in single-channel activity of skeletal muscle ryanodine receptors after removal of FKBP12. Biophysical journal 72, 146-162 (1997). 102. Wang, T., Donahoe, P.K. & Zervos, A.S. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science (New York, N.Y 265, 674-676 (1994). 103. Lopez-Ilasaca, M., Schiene, C., Kullertz, G., Tradler, T., Fischer, G. & Wetzker, R. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. The Journal of biological chemistry 273, 9430-9434 (1998). 104. Chelu, M.G., Danila, C.I., Gilman, C.P. & Hamilton, S.L. Regulation of ryanodine receptors by FK506 binding proteins. Trends in cardiovascular medicine 14, 227-234 (2004). 105. Huse, M., Chen, Y.G., Massague, J. & Kuriyan, J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 96, 425-436 (1999). 106. Aldape, R.A., Futer, O., DeCenzo, M.T., Jarrett, B.P., Murcko, M.A. & Livingston, D.J. Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. The Journal of biological chemistry 267, 16029-16032 (1992). 107. Ruegger, A., Kuhn, M., Lichti, H., Loosli, H.R., Huguenin, R., Quiquerez, C. & von Wartburg, A. [Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]. Helvetica chimica acta 59, 1075-1092 (1976). 108. Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S. & Schreiber, S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756-758 (1994). 109. Butcher, S.P., Henshall, D.C., Teramura, Y., Iwasaki, K. & Sharkey, J. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 17, 6939-6946 (1997). 110. Herdegan, T., Fischer, G. & Bold, B.G. Immunophilin ligands as a novel treatment of neurological disorders. Trends in pharmacological sciences 21, 3-5 (2000). 111. Wakita, H., Tomimoto, H., Akiguchi, I. & Kimura, J. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. Brain research 792, 105-113 (1998). 112. Dawson, T.M., Steiner, J.P., Dawson, V.L., Dinerman, J.L., Uhl, G.R. & Snyder, S.H. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America 90, 9808-9812 (1993). 113. Klettner, A., Baumgrass, R., Zhang, Y., Fischer, G., Burger, E., Herdegen, T. & Mielke, K. The neuroprotective actions of FK506 binding protein ligands: neuronal survival is triggered by de novo RNA synthesis, but is independent of inhibition of JNK and calcineurin. Brain research 97, 21-31 (2001). 114. Steiner, J.P., Dawson, T.M., Fotuhi, M. & Snyder, S.H. Immunophilin regulation of neurotransmitter release. Molecular medicine (Cambridge, Mass 2, 325-333 (1996). 115. Gold, B.G., Katoh, K. & Storm-Dickerson, T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci 15, 7509-7516 (1995). 116. Klettner, A. & Herdegen, T. The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response. British journal of pharmacology 138, 1004-1012 (2003). 117. Orozco, M., Tirado-Rives, J. & Jorgensen, W.L. Mechanism for the rotamase activity of FK506 binding protein from molecular dynamics simulations. Biochemistry 32, 12864-12874 (1993). 118. DeCenzo, M.T., Park, S.T., Jarrett, B.P., Aldape, R.A., Futer, O., Murcko, M.A. & Livingston, D.J. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. Protein engineering 9, 173-180 (1996). 119. Suen, K.C., Lin, K.F., Elyaman, W., So, K.F., Chang, R.C. & Hugon, J. Reduction of calcium release from the endoplasmic reticulum could only provide partial neuroprotection against beta-amyloid peptide toxicity. Journal of neurochemistry 87, 1413-1426 (2003). 120. Kato, H., Oikawa, T., Otsuka, K., Takahashi, A. & Itoyama, Y. Postischemic changes in the immunophilin FKBP12 in the rat brain. Brain research 84, 58-66 (2000). 121. Avramut, M. & Achim, C.L. Immunophilins in nervous system degeneration and regeneration. Current topics in medicinal chemistry 3, 1376-1382 (2003). 122. 劉姵斈. 對與AICD產生交互作用之蛋白之研究. 國立臺灣大學醫學院藥學研究所碩士論文 (民國九十二年七月). 123. 邵獻偉. FKBP12與APP intracellular domain交互作用之研究. 國立臺灣大學醫學院藥學研究所碩士論文 (民國九十四年七月). 124. Lee, R.K. & Wurtman, R.J. Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. Annals of the New York Academy of Sciences 920, 261-268 (2000). 125. Chen, Q.S., Wei, W.Z., Shimahara, T. & Xie, C.W. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiology of learning and memory 77, 354-371 (2002). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28971 | - |
dc.description.abstract | 過去對於AICD的研究發現某些伴隨蛋白(chaperone)可以和AICD產生交互作用。舉例來說,使用酵母菌雙雜交(yeast two-hybrid)篩選發現有PPIase活性之伴隨蛋白同時也是免疫親和素(immunophilin)的FKBP12可以和AICD產生交互作用。另一個PPIase—Pin1,也被報導參與amyloidogenic APP代謝過程。由此或許可以暗示FKBP12所扮演的角色。在這個研究中,truncated形式的FKBP12被用來確認和AICD間的交互作用,而結果顯示包含一些FKBP12結合區域的33-41片段可能對於FKBP12-AICD交互作用扮演著重要角色。在這個研究中,truncated形式的FKBP12被用來確認和AICD間的交互作用,而結果顯示包含一些FKBP12結合區域的33-41片段可能對於FKBP12-AICD交互作用扮演著重要角色。β-半乳醣苷酶試驗因而被用來檢視是否當免疫抑制藥物FK506或cyclosporin A的存在會影響FKBP12和AICD之間的交互作用。另外以FKBP12為標靶的另一種藥物—Rapamycin也以同樣的實驗來測試。實驗結果顯示未和FKBP12產生交互作用的cyclosporin A並不能阻斷FKBP12-AICD的交互作用,但是FK506和rapamycin可以。依據這個結果,我們認為FKBP12的疏水性binding pocket可能對於與AICD的交互作用而言是重要的。在HEK293T細胞株中過量表現APP和FKBP12顯示FKBP12可能可以改變C99和C83的量,而這結果可以被FK506反轉。這可能是FK506對於神經退化疾病的保護作用中的原因之一。 | zh_TW |
dc.description.abstract | Past studies of AICD indicated that some chaperones can interact with AICD. For example, FKBP12, a chaperone and an immunophilin with PPIase activity, was found to interact with AICD by yeast two-hybrid screening. It was reported that Pin1, another PPIase, was involved in the amyloidogenic APP processing. This might hint the role of FKBP12. In this study, truncated forms of FKBP12 were checked for their ability to interact with AICD, and the results showed residues 33-41 containing several FK506 binding residues might play an important role in the FKBP12-AICD interaction. β-galactosidase assay was therefore used to see whether the presence of certain immunosuppresants such as FK506 or cyclosporin A affects the interaction between FKBP12 and AICD. Rapamycin, another compound targeting to FKBP12, was also tested using the same method. Our result indicate that cyclosporin A, which does not interact with FKBP12, could not block FKBP12-AICD interaction, but FK506 or rapamycin could. According to these results, we suggest that hydrophobic binding pockets of FKBP12 might be important for the interaction with AICD. Overexpression of APP and FKBP12 in HEK293T cell line showed that FKBP12 could alter the levels of C99 and C83, and this results could be reserved by FK506. This may be a point of protective activity of FKBP12 in neurodegeneration dissease. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T00:32:32Z (GMT). No. of bitstreams: 1 ntu-96-R94423027-1.pdf: 3348997 bytes, checksum: 113dbe7dbec13bc8604219d93f143b58 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 口試委員會審定書(I)
謝辭(II) 中文摘要(III) 英文摘要(IV) 英文縮寫表(V) 序論(1) 1、阿茲海默氏症(Alzheimer’s disease)(1) 2、FKBP12 (FK506 binding protein 12) (8) 3、APP與FKBP12(10) 材料與方法(12) 一、材料(12) 二、建構質體DNA(13) 三、AICD與FKBP12交互作用的探討—酵母菌雙雜交試驗(13) 四、AICD與FKBP12交互作用的探討—β-半乳醣苷酶試驗(16) 五、過量表現FKBP12對APP代謝過程之影響(17) 實驗結果(20) 一、確認AICD和FKBP12之間的交互作用(20) 二、FK506、rapamycin、cyclosporin A對AICD和FKBP12交互作用的影響(21) 三、FKBP12對APP代謝過程的影響(23) 四、FK506對FKBP12改變APP代謝過程的影響(26) 討論(27) 圖表(28) 參考文獻(42) | |
dc.language.iso | zh-TW | |
dc.title | FK506對於APP的蛋白質交互作用及代謝過程之影響 | zh_TW |
dc.title | Investigation of the effect of FK506 on protein-protein interaction and processing of APP | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 顧記華(Jih-Hwa Guh),李財坤(Tsai-Kun Li),兵岳忻(Yueh-Hsin Ping) | |
dc.subject.keyword | 老年癡呆, | zh_TW |
dc.subject.keyword | Alzheimer,APP,AICD,FKBP12, | en |
dc.relation.page | 53 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 3.27 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。